PTGES3L-AARSD1

Across TCGA pan-cancer cohorts, PTGES3L-AARSD1 RNA differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of PTGES3L-AARSD1’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where PTGES3L-AARSD1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types PTGES3L-AARSD1 is over-expressed in tumor, although a few such as BLCA and UCEC show the opposite, repressed pattern.

HNSC, BLCA, and LUSC are the cancer types where PTGES3L-AARSD1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PTGES3L-AARSD1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	III,IV	+0.356	<.001	12	view →
BLCA	Male	III,IV	−1.058	<.001	8	view →
LUSC	All	All	+0.161	<.001	5	view →
LIHC	All	All	+0.028	.001	4	view →
UCEC	All	All	−0.170	.044	2	view →
PRAD	All	All	−0.088	.009	2	view →
KICH	Male	IV	+0.073	.005	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

PTGES3L-AARSD1–HNSC

Open the HNSC breakdown →